Cardiolrx
Recurrent Pericarditis
Phase III
Recruiting
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
Nov 25, 2024
―
Cardiolrx
Recurrent Pericarditis
Phase II
Completed
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Aug 08, 2022
―
Cardiolrx
Acute Myocarditis
Phase II
Completed
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
Sep 25, 2021
―
Cannabidiol, Pharmaceutically Produced With < 5 Ppm Thc
Cardiovascular Diseases, Covid-19, Cardiovascular Risk Factor
Phase II/III
Terminated
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Nov 02, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cardiol Therapeutics (CT9) have in its pipeline
CT9 is currently developing the following drugs: Cardiolrx, Cardiolrx, Cardiolrx. These drug candidates are in various stages of clinical development as the company works toward FDA approval.